Type III allergic inflammation model animal

Details Type III allergic inflammation model animal Type III allergic inflammation model animal

2007-10-16

2007-10-16

Bertoglio, Valarie (Department: 1632)

Multicellular living organisms and unmodified parts thereof and

Nonhuman animal

Transgenic nonhuman animal

C800S008000, C800S014000, C800S023000

Reexamination Certificate

active

10362593

ABSTRACT:
The present invention provides an experimental model animal which does not develop anaphylaxis, a type I allergy, can specifically induce Arthus reaction, a type III allergy, is not affected by type I allergy and evaluates type III allergy inflammation individually, and a method of screening a reaction accelerating or inhibitory substance in a type III allergy reaction through FcγRIII by using said experimental model animal. In order to eliminate FcγRIIB that demonstrates suppressive action to response through FrγRIII, a mouse wherein the deletion mutation of both molecules of Lyn and FcγRIIB are homozygotic (Lyn−IIB−) was generated by mating Lyn knockout mouse (Lyn−/−) and FcγRIIB knockout mouse (FcγRIIB−/−), and was used to measure and evaluate the deficiency of FcγRIII function in systemic passive anaphylaxis and the reduction of FcγRIII function in a bone marrow-derived mast cell, or the like.

REFERENCES:
patent: 5859314 (1999-01-01), Hibbs et al.
patent: WO97/14791 (1997-04-01), None
Campbell and Wilmut, 1997, Totipotency or multipotency of cultured cells: applications and progress, Theriogenology, vol. 47, pp. 63-72.
Mullins, 1996, J. Clin. Invest., vol. 97, pp. 1557-1560.
Nishizumi, H et al. 1995, Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice, Immunity, 3:549-560.
Takae, Y et al. Mar. 2001, Lyn is essential for Fcg Receptor III-mediated systemic anaphylaxis but not for the Arthus reaction, J Exp Med., 5:563-571.
Hibbs, M.L. et al., “Multiple Defects in the Immune System of Lyn-Deficient Mice, Culminating in Autoimmune Disease”, Cell, vol. 83, pp. 301-311, Oct. 20, 1995.
Oliver, J.M. et al., “Immunologically mediated signaling in basophils and mast cells: finding therapeutic targets for allergic diseases in the human Fc ε RI signaling pathway”, Immunopharmacology, vol. 48, pp. 269-281, Jul. 25, 2000.
Takai, T. et al., “Regulation of murine hypersensitive responses by Fc receptors”, Allergology International, vol. 47, No. 2, pp. 75-83, 1998.
Dombrowicz, D. et al., “Abolition of Anaphylaxis by Targeted Disruption of the High Affinity Immunoglobulin E Receptor @ Chain Gene”, Cell, vol. 75, pp. 969-976, Dec. 3, 1993.
Takai, T. et al., “FcR γ Chain Deletion Results in Pleiotrophic Effector Cell Defects”, Cell, vol. 76, pp. 519-529, Feb. 11, 1994.
Takai, T. et al., “Augmented humoral and anaphylactic responses in FcγRII-deficient mice”, Nature, vol. 379, pp. 346-349, Jan. 1996.
Hiroshi Fujiwara et al., “The absence of IgE antibody-mediated augmentation of immune responses in CD23-deficient mice”, Immunology, vol. 91, pp. 6835-6839, Jul. 1994.
Diana L. Sylvestre et al., “Fc Receptors Initiate the Arthus Reaction: Redefining the Inflammatory Cascade”, Science, vol. 265, pp. 1095-1098, Aug. 19, 1994.
Takae Yuasa et al., “Deletion of Fcγ Receptor IIB Renders H-2 Mice Susceptible to Collagen-induced Arthritis”, J. Exp. Med., vol. 189, No. 1, pp. 187-194, Jan. 4, 1999.
Sandra Kleinau et al., “Induction and Suppression of Collagen-induced Arthritis Is Dependent on Distinct Fcγ Receptors”, J. Exp. Med., vol. 191, No. 9, pp. 1611-1616, May 1, 2000.
Yusuke Suzuki et al., “Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis”, Kidney International, vol. 54, pp. 1166-1174, Jan. 26, 1998.
Hisashi Wakayama et al., “Abolition of anti-glomerular basement membrane antibody-mediated glomerulonephritis in FcRγ-deficient mice”, Eur. J. Immunol., vol. 30, pp. 1182-1190, 2000.
Raphael Clynes et al., “Uncoupling of Immune Complex Formation and Kidney Damage in Autoimmune Glomerulonephritis”, Science, vol. 279, pp. 1052-1054, Feb. 13, 1998.
Akira Nakamura et al., “Fcγ Receptor IIB-deficient Mice Develop Goodpasture's Syndrome upon Immunization with Type IV Collagen: A Novel Murine Model for Autoimmune Glomerular Basement Membrane Disease”, J. Exp. Med., vol. 191, No. 5, pp. 899-905, Mar. 6, 2000.
Jeffrey V. Ravetch et al., “Divergent Roles For Fc Receptors and Complement In Vivo”, Annu. Rev. Immunol. vol. 16, pp. 421-432, 1998.
Marc Daëron, “Fc Receptor Biology”, Annul. Rev. Immunol. vol. 15, pp. 203-234, 1997.
David Dombrowicz et al., “Absence of FcRI Chain Results in Upregulation of FcγRII-dependent Mast Cell Degranulation and Anaphylaxis”, The J. Clin. Invest., vol. 99, No. 5, pp. 915-925, Mar. 1997.
Miyajima et al., “Systemic Anaphylaxis in the Mouse Can Be Mediated Largely through IgG1 and FcγRIII”, The J. Clin. Invest., vol. 99, No. 5, pp. 901-914, Mar. 1997.
Azusa Ujike et al., “Modulation of Immunoglobulin (Ig) E-mediated Systemic Anaphylaxis by Low-Affinity Fc Receptor for IgG”, J. Exp. Med., vol. 189, No. 10, pp. 1573-1579, May 17, 1999.
Elizabeth A. Finch et al., “Local calcium signalling by inositol-1,4,5-trisphosphate in Purkinje cell dendrites”, Nature, vol. 396,24/31, pp. 753-756, Dec. 1998.
Carsten Schiller et al., “Mouse FcγRII is a negative regulator of FcγRIII in IgG immune complex-triggered inflammation but not in autoantibody-induced hemolysis”, Eur. J. Immunol, vol. 30, pp. 481-490, 2000.
Margaret L. Hibbs et al., “Lyn, ascr-like Tyrosine Kinase”, Int. J. Biochem Cell Biol., vol. 29, No. 3, pp. 397-400, 1997.
Tomohiro Kurosaki, “Genetic Analysis of B Cell Antigen Receptor Signaling”, Annu. Rev. Immunol., vol. 17, pp. 555-592, 1999.
Hirofumi Nishizumi et al., “Impaired Tyrosine Phosphorylation and Ca2+Mobilization, but Not Degranulation, in Lyn-Deficient Bone Marrow-Derived Mast Cells”, The J. of Immunology, pp. 2350-2355, 1997.
Y. Zhang et al., “Role of mast cells in plasma permeation due to immune injury of the skin basement membrane”, Immunology, vol. 77, pp. 422-427, 1992.
Peter P. Bradley, et al., “Measurement of Cutaneous Inflammation: Estimation of Neutrophil Content with an Enzyme Marker”, The J. of Invest. Dermatology, vol. 78, pp. 206-209, 1982.
Y. Okayama et al., “Multiple Cytokine mRNA Expression in Human Mast Cells Stimulated via FcεRI”, Int. Arch Allergy Immunol, vol. 107, pp. 158-159, 1995.
Parris R. Burd et al., “Interleukin 3-Dependent and-Independent Mast Cells Stimulated with IgE and Antigen Express Multiple Cytokines”, J. Exp. Med, vol. 170, pp. 245-257, Jul. 1989.
John R. Gordon et al., “Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin”, Nature, vol. 346, pp. 274-276, Jul. 19, 1990.
Marshall Plaut et al., “Mast cell lines produce lymphokines in response to cross-linkage of FcεRI or to calcium ionophores”, Nature, vol. 399, pp. 64-67, May 4, 1989.
Aribert Stief et al., “Mice Deficient in CD23 Reveal Its Modulatory Role in IgE Production but Not Role in T and B Cell Development”, J. of Immunology, pp. 3378-3390, 1994.
Grzegorz Grynkiewicz et al., “A New Generation of Ca2+Indicators with Greatly Improved Fluorescence Properties”, The J. of Biological Chem., vol. 260, No. 6, pp. 3440-3450, Mar. 25, 1985.
Yuasa et al., Lyn is Essential for Fcγ Receptor III-mediated Systemic Anaphylaxis but Not for the Arthus Reaction, J. Exp. Med., vol. 193, No. 5. Mar. 5, 2001 (pp. 563-571)—XP-002426009.
De Andres, Belen et al., A regulatory role for Fcγ Receptors (CD16 and CD32) in hematopoiesis—Immunology Letters 68, (1999), pp. 109-113—XP-002426010.
De Andres, Belen et al., A regulatory role for Fcγ Receptors (CD16 and CD32) in the development of Murine B Cells—Blood vol. 92, No. 8, Oct. 15, 1998, pp. 2823-2829—XP-002426011.
Wang et al., Altered Antigen Receptor

Affiliated with

Also associated with

Rating

Type III allergic inflammation model animal does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Type III allergic inflammation model animal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Type III allergic inflammation model animal will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3879639